Hosted on MSN2mon
Larimar started at buy by Truist on Friedreich's ataxia drug
Truist has initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory updates for its drug candidate nomla for Friedreich ...
Transparency Market Research10mon
Ataxia Treatment Market
Ataxia Treatment Market, trends, and advancements in neurological disorder treatments. Discover growth drivers, key players, and forecasts up to 2035 ...